Development and intra-renal delivery of renal progenitor organoids for effective integration in vivo
Renal progenitor organoids have been proposed as a source of tissue for kidney regeneration; however, their clinical translatability has not been demonstrated due to an inability to mass-produce comprehensive renal progenitor organoids and the lack of an effective intra-renal delivery platform that facilitates rapid integration into functionally meaningful sites. This study addresses these shortcomings. Human-induced pluripotent stem cells were differentiated into renal progenitor cells using an established protocol and aggregated using a novel assembly method to produce high yields of organoids. Organoids were encapsulated in collagen-based scaffolds for in vitro study and in vivo implantation into mouse renal cortex. In vitro, the organoids demonstrated sustained cell viability and renal structure maturation over time. In vivo delivered organoids showed rapid integration into host renal parenchyma while showing tubular and glomerular-like structure development and maturity markers. This proof-of-concept study presents many promising results, providing a system of renal organoid formation and delivery that may support the development of clinically translatable therapies and the advancement of in vitro renal organoid studies.
Authors
- Anthony Atala (ORCID: https://orcid.org/0000-0001-8186-2160)
- Ickhee Kim (ORCID: https://orcid.org/0000-0002-8836-5527)
- Diana Lim (ORCID: https://orcid.org/0000-0003-2110-5787)
- Jihyun Kim (ORCID: https://orcid.org/0000-0002-2466-1925)
- James J. Yoo (ORCID: https://orcid.org/0000-0002-7827-3848)
- Qianqian Song (ORCID: https://orcid.org/0000-0002-4455-5302)
- John David Jackson
Institutions
- Forest Institute (US)
- Wake Forest University (US)
Publication Details
- Journal
- Stem Cells Translational Medicine
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1093/stcltm/szae078
- Citations
- 4
- Primary Topic
- Renal and related cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Institutes of Health